113 related articles for article (PubMed ID: 22130178)
41. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.
Vieta E; Montgomery S; Sulaiman AH; Cordoba R; Huberlant B; Martinez L; Schreiner A
Eur Neuropsychopharmacol; 2012 Nov; 22(11):825-35. PubMed ID: 22503488
[TBL] [Abstract][Full Text] [Related]
42. Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice.
Novick D; Reed C; Haro JM; Gonzalez-Pinto A; Perrin E; Aguado J; Tohen M
Int Clin Psychopharmacol; 2010 Sep; 25(5):257-63. PubMed ID: 20531011
[TBL] [Abstract][Full Text] [Related]
43. Second-generation antipsychotics for anxiety disorders.
Depping AM; Komossa K; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008120. PubMed ID: 21154392
[TBL] [Abstract][Full Text] [Related]
44. Acute and continuation risperidone monotherapy in mania.
Vieta E; Brugué E; Goikolea JM; Sánchez-Moreno J; Reinares M; Comes M; Colom F; Martínez-Arán A; Benabarre A; Torrent C
Hum Psychopharmacol; 2004 Jan; 19(1):41-5. PubMed ID: 14716711
[TBL] [Abstract][Full Text] [Related]
45. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
[TBL] [Abstract][Full Text] [Related]
46. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
Adams JB; Pyke RE; Costa J; Cutler NR; Schweizer E; Wilcox CS; Wisselink PG; Greiner M; Pierce MW; Pande AC
J Clin Psychopharmacol; 1995 Dec; 15(6):428-34. PubMed ID: 8748432
[TBL] [Abstract][Full Text] [Related]
47. Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale.
Kinrys G; Bowden CL; Nierenberg AA; Hearing CM; Gold AK; Rabideau DJ; Sylvia LG; Gao K; Kamali M; Bobo WV; Tohen M; Deckersbach T; McElroy SL; Ketter TA; Shelton RC; Friedman ES; Calabrese JR; McInnis MG; Kocsis J; Thase ME; Singh V; Reilly-Harrington NA
J Affect Disord; 2019 Mar; 246():126-131. PubMed ID: 30580198
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
49. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
Katzman MA; Vermani M; Jacobs L; Marcus M; Kong B; Lessard S; Galarraga W; Struzik L; Gendron A
J Anxiety Disord; 2008 Dec; 22(8):1480-6. PubMed ID: 18455360
[TBL] [Abstract][Full Text] [Related]
50. Is There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA Guidelines.
Perna G; Alessandra A; Raffaele B; Elisa M; Giuseppina D; Paolo C; Maria N; Daniela C
Int J Mol Sci; 2016 Apr; 17(4):551. PubMed ID: 27089322
[TBL] [Abstract][Full Text] [Related]
51. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.
Katzman MA; Brawman-Mintzer O; Reyes EB; Olausson B; Liu S; Eriksson H
Int Clin Psychopharmacol; 2011 Jan; 26(1):11-24. PubMed ID: 20881846
[TBL] [Abstract][Full Text] [Related]
52. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.
Amsterdam JD; Wang CH; Shwarz M; Shults J
J Affect Disord; 2009 Jan; 112(1-3):219-30. PubMed ID: 18486235
[TBL] [Abstract][Full Text] [Related]
53. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial.
Nejtek VA; Avila M; Chen LA; Zielinski T; Djokovic M; Podawiltz A; Kaiser K; Bae S; Rush AJ
J Clin Psychiatry; 2008 Aug; 69(8):1257-66. PubMed ID: 18681757
[TBL] [Abstract][Full Text] [Related]
54. Clinical features and patterns of psychopharmacological prescription in bipolar patients with vs without anxiety disorders at onset.
Galimberti C; Caricasole V; Bosi MF; Viganò CA; Ketter TA; Dell'Osso B
Early Interv Psychiatry; 2020 Dec; 14(6):714-722. PubMed ID: 31733039
[TBL] [Abstract][Full Text] [Related]
55. Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea.
Woo YS; Bahk WM; Jon DI; Chung SK; Lee SY; Ahn YM; Pae CU; Cho HS; Kim JG; Hwang TY; Lee HS; Min KJ; Lee KU; Yoon BH
Psychiatry Clin Neurosci; 2010 Feb; 64(1):28-37. PubMed ID: 19895394
[TBL] [Abstract][Full Text] [Related]
56. Impact of comorbid anxiety disorders and obsessive-compulsive disorder on 24-month clinical outcomes of bipolar I disorder.
Kim SW; Berk L; Kulkarni J; Dodd S; de Castella A; Fitzgerald PB; Amminger GP; Berk M
J Affect Disord; 2014 Sep; 166():243-8. PubMed ID: 25012437
[TBL] [Abstract][Full Text] [Related]
57. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
[TBL] [Abstract][Full Text] [Related]
58. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder.
Bartzokis G; Lu PH; Turner J; Mintz J; Saunders CS
Biol Psychiatry; 2005 Mar; 57(5):474-9. PubMed ID: 15737661
[TBL] [Abstract][Full Text] [Related]
59. Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania.
Yatham LN; Binder C; Kusumakar V; Riccardelli R
Int Clin Psychopharmacol; 2004 Mar; 19(2):103-9. PubMed ID: 15076019
[TBL] [Abstract][Full Text] [Related]
60. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone.
Kemp DE; Johnson E; Wang WV; Tohen M; Calabrese JR
J Clin Psychiatry; 2011 Sep; 72(9):1236-41. PubMed ID: 21457677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
